🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study Comparing SBS and LRTI for Treatment of CMC Arthritis

RecruitingNAAges 50 Years - anyAllFraser Orthopaedic Research Society
NCT05111405 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A multi-center, randomized control trial comparing the two standard of care surgical treatments for CMC arthritis ; trapezial excision with or without soft tissue interposition and /or ligament reconstruction (LRTI) versus the suture button suspension arthroplasty (SBS). Patient reported outcomes will be collected at 6 and 6 weeks, 3, 6, and 12 months.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age fifty years or older * Isolated carpometacarpal (trapeziometacarpal) osteoarthritis * Failure to respond to non-operative management * Willing and able to consent on their own behalf and follow the protocol and clinical visits as described * Able to read and understand English or have interpreter available Exclusion Criteria: * Previous surgery for CMC arthritis * Duration of symptoms for less than 6 months * Greater than or equal to 30 degrees of ipsilateral metacarpophalangeal (MCP) hyperextension * Scaphotrapeziotrapezoidal (stage 4 CMC) arthritis * Other significant ipsilateral wrist or hand pathology * A history of inflammatory arthropathy * A requirement for concomitant surgery for another condition * Any previous hand or wrist fracture * Likely problems, in the judgement of the investigators, with maintaining follow-up (i.e. patients with no fixed address, not mentally competent to give consent, intellectually challenged patients without adequate support, etc.)
💊

What it tests

  • CMC Arthroplasty
📍

Where

2 sites
South Campus Research Unit for Bone and Soft Tissue
Calgary, Canada
Fraser Orthopaedic Research Society
New Westminster, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy